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Introduction
The role of B lymphocyte stimulator (Blys) in Childhood
onset Systemic Lupus Erythematosus (cSLE) has not
been elucidated.
Objectives
To investigate the role of Blys and its association with
biomarkers related with the cSLE disease activity and
severity.
Methods
34 cSLE patients (study group), 51 with other rheumatic
or autoimmune diseases and 26 healthy children (control
groups) were studied. For evaluating the disease activity,
SLEDAI and ECLAM scores were used. For estimating the
disease severity the criteria were: involvement of 3 vital
organs (kidneys or CNS or blood or combination of ≥2
organs), increased anti-dsDNA titres, low C3 /C4 concen-
trations and high concentrations of serum IFN-a and
HMGB1 (High mobility group box 1) protein.
Results
Mean Blys levels were significantly higher in cSLE patients
in respect to patients of all control groups, in patients with
active as compared with patients with inactive disease and
in patients with vital organ involvement as compared with
patients without such involvement. Moreover, mean Blys
levels were positively correlated with anti-DNA titer,
IFN-a and HMGB1 levels but negatively correlated with
C3 /C4 concentrations.
Conclusion
Taking together, results of our study indicate that: high
levels of Blys are mainly found in serum of jSLE patients
and they may be involved in the increased anti-DNA plus
other autoantibody production. Moreover, they are asso-
ciated with the disease activity and severity, meaning that
Blys is a specific biomarker for the selection of patients
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